Chondrial Therapeutics was formed to commercialize a proprietary protein replacement platform for mitochondrial diseases.
IBJ 08.14Startup has rare disease in its sights.
Development MilestoneThe company’s lead drug candidate has been accepted for further development by the National Institutes of Health.
Update 05.15Chondrial Therapeutics is pleased to announce several development milestones.
Technologies We Use
Chondrial Therapeutics has developed a mitochondrial protein replacement therapy for FRDA based on cell penetrant technology that can also serve as a platform technology for other mitochondrial disorders.
Published Proof of Principle
We have published proof of principle for replacing Frataxin protein in FRDA knockout animals and continue to develop further proof of concept with our targeted lead compound. Frataxin knockout mice live significantly longer with TAT-Frataxin fusion protein injections because heart and neurologic function, growth, and biochemistry are improved.
Chondrial Therapeutics was formed to commercialize a proprietary protein replacement platform for mitochondrial diseases. This fusion protein platform was developed by Dr. Mark Payne who currently serves as the Chief Scientific Officer. Our focus is on Orphan diseases and Friedreich's Ataxia is our initial target.